Intellia Therapeutics Head office building


Intellia Therapeutics to Present at November Investor Healthcare Conferences

October 31, 2016

CAMBRIDGE, Mass., Oct. 31, 2016 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on the development of potentially curative therapeutics using CRISPR/Cas9 technology, announced that senior company leaders will present at key November investor healthcare conferences, including the 25th Annual Credit Suisse Healthcare Conference and the Jefferies 2016 London Healthcare Conference.

Details of the upcoming presentations are as follows:

Monday, November 7th
25th Annual Credit Suisse Healthcare Conference, 2016
Location: Scottsdale, Arizona
Presentation Time: 11:30 AM MST

Thursday, November 17th
Jefferies 2016 London Healthcare Conference
Location: London, England
Presentation Time: 3:20 PM GMT

Individuals may access the presentations for each conference via live webcast on the Intellia website at under "Events & Presentations" in the "Investor Relations" section. A replay of the webcast will be available on this site for 90 days following the live event.

About Intellia Therapeutics

Intellia Therapeutics is a leading genome editing company, focused on the development of proprietary, potentially curative therapeutics using the CRISPR/Cas9 system. Intellia believes the CRISPR/Cas9 technology has the potential to transform medicine by permanently editing disease-associated genes in the human body with a single treatment course. Our combination of deep scientific, technical and clinical development experience, along with our leading intellectual property portfolio, puts us in a unique position to unlock broad therapeutic applications of the CRISPR/Cas9 technology and create a new class of therapeutic products. Learn more about Intellia Therapeutics and CRISPR/Cas9 at; Follow us on Twitter @intelliatweets.

Media Contact:

Jennifer Mound Smoter
Chief External Affairs & Communications Officer
+1 857-706-1071

Investor Contacts:

John GrazianoTrout Group
+1 646-378-2942

Chad RubinTrout Group
+1 646-378-2947

Primary Logo

Intellia Therapeutics, Inc.